Clinical Trial · NCT00025532

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer

Overview

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for gastrointestinal cancer. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody therapy in treating patients who have gastrointestinal cancer.

Sponsor

University of California, San Francisco

Phase

Phase 1

Contacts

Margaret A. Tempero, MD (STUDY_CHAIR)

ClinicalTrials.gov

NCT00025532